🔎 Trials Near Me

Utama › Kanser Paru-paru Bukan Sel Kecil › Texas › Austin

Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Austin, TX

30 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Austin (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Mengambil pesertaFasa 1/2
  • New Experimental Therapeutics - NEXT Oncology, Austin
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Mengambil pesertaFasa 1
  • Exelixis Clinical Site #46, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05176483

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Mengambil pesertaFasa 3
  • Texas Oncology-Austin Central, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07361497

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Mengambil pesertaFasa 3
  • Texas Oncology - South Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Mengambil pesertaFasa 3
  • Texas Oncology- Central South., Austin
  • Texas Oncology Central South, Austin
  • Texas Oncology- Central South., Austin
  • dan 1 lagi
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07144280

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Mengambil pesertaFasa 3
  • Texas Oncology - Central/South Texas, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07222566

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Mengambil pesertaFasa 1/2
  • Next Oncology - Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07488676

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Mengambil pesertaFasa 3
  • Clinical Study Site, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06767514

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Mengambil pesertaFasa 1/2
  • Texas Oncology (Balcones) - SCRI, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05267626

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Mengambil pesertaFasa 2/3
  • Local Institution - 007-892-B, Austin
  • Local Institution - 007-892-A, Austin
  • USOR - Texas Oncology - Dallas Fort Worth (DFW) - South Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04613596

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Mengambil pesertaFasa 1
  • NEXT Oncology - Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Mengambil pesertaFasa 3
  • USO - Texas Oncology, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Oncology Texas, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07361562

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Mengambil pesertaFasa 3
  • Research Site, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07291037

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Oncology - Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT07444814

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Mengambil pesertaFasa 1/2
  • Texas Oncology - Central / South Texas, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05579366

Study of XB010 in Subjects With Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT06545331

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Mengambil pesertaFasa 1
  • NEXT Texas LLC - Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Jun 2026 · NCT07503808

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Texas LLC - Austin, Austin
Umur 18 hingga 99 · Semua jantina · Dikemas kini 16 Jun 2026 · NCT07540572

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Mengambil pesertaFasa 2
  • Texas Oncology - Austin Central, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT06463665

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Mengambil pesertaFasa 3
  • Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Mei 2026 · NCT07154706

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Mengambil pesertaFasa 1/2
  • University of Texas at Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Oncology, Austin, TX 78758
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Apr 2026 · NCT06451497

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Mengambil pesertaFasa 1
  • Dren Investigational Site, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jan 2026 · NCT06999187

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Research Site 135, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Nov 2025 · NCT05914116

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Mengambil pesertaFasa 2
  • TxO Central/South, Texas Oncology -Central/South Texas, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2025 · NCT06868485

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Mengambil pesertaFasa 1/2
  • NEXT Austin, Austin
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jan 2025 · NCT06090266

Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain

Kajian lain di Austin

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.